Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105293284 | 10529328 | 4 | F | 20160812 | 20141021 | 20160816 | EXP | CA-ROCHE-1470925 | ROCHE | REPORTER KNOWN TO HEALTH AUTHORITY. UNKNOWN. UNKNOWN ;:-. | 36.00 | YR | F | Y | 0.00000 | 20160817 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105293284 | 10529328 | 1 | PS | MYCOPHENOLATE MOFETIL. | MYCOPHENOLATE MOFETIL | 1 | Unknown | U | 50722 | ||||||||||
| 105293284 | 10529328 | 2 | I | RIBAVIRIN. | RIBAVIRIN | 1 | Unknown | U | 21511 | TABLET | |||||||||
| 105293284 | 10529328 | 3 | I | PEGASYS | PEGINTERFERON ALFA-2A | 1 | Unknown | U | 103964 | SOLUTION FOR INJECTION | |||||||||
| 105293284 | 10529328 | 4 | I | RIBAVIRIN. | RIBAVIRIN | 1 | Unknown | U | 21511 | ||||||||||
| 105293284 | 10529328 | 5 | I | RIBAVIRIN. | RIBAVIRIN | 1 | Unknown | U | 21511 | 400 | MG | BID | |||||||
| 105293284 | 10529328 | 6 | I | RIBAVIRIN. | RIBAVIRIN | 1 | Unknown | U | 21511 | 200 | MG | BID | |||||||
| 105293284 | 10529328 | 7 | SS | Peg-Interferon Alfa 2a | PEGINTERFERON ALFA-2A | 1 | Unknown | U | 103964 | ||||||||||
| 105293284 | 10529328 | 8 | I | VICTRELIS | BOCEPREVIR | 1 | Unknown | U | 0 | 800 | MG | CAPSULE | TID | ||||||
| 105293284 | 10529328 | 9 | I | PEGINTERFERON ALFA-2B | PEGINTERFERON ALFA-2B | 1 | Unknown | U | 0 | 400 | MG | BID | |||||||
| 105293284 | 10529328 | 10 | I | PEGINTERFERON ALFA-2B | PEGINTERFERON ALFA-2B | 1 | Unknown | U | 0 | 48 | UG | ||||||||
| 105293284 | 10529328 | 11 | I | PROGRAF | TACROLIMUSTACROLIMUS ANHYDROUS | 1 | Unknown | U | 0 | .5 | MG | CAPSULE | BID | ||||||
| 105293284 | 10529328 | 12 | I | PROGRAF | TACROLIMUSTACROLIMUS ANHYDROUS | 1 | Unknown | U | 0 | .5 | MG | CAPSULE | Q3W | ||||||
| 105293284 | 10529328 | 13 | I | PROGRAF | TACROLIMUSTACROLIMUS ANHYDROUS | 1 | Unknown | U | 0 | CAPSULE | |||||||||
| 105293284 | 10529328 | 14 | I | PEGINTERFERON ALFA-2B/RIBAVIRIN | PEGINTERFERON ALFA-2BRIBAVIRIN | 1 | Unknown | U | 0 | 400 | MG | BID | |||||||
| 105293284 | 10529328 | 15 | I | PEGINTERFERON ALFA-2B/RIBAVIRIN | PEGINTERFERON ALFA-2BRIBAVIRIN | 1 | Unknown | U | 0 | 200 | MG | BID | |||||||
| 105293284 | 10529328 | 16 | I | VICTRELIS TRIPLE | BOCEPREVIRPEGINTERFERON ALFA-2BRIBAVIRIN | 1 | Unknown | BOCEPREVIR CAPSULE 200MG; RIBAVIRIN CAPSULE 200MG; PEGINTERFERON ALFA-2B, POWDER FOR SOLUTION | U | 0 | |||||||||
| 105293284 | 10529328 | 17 | I | INTRON A | INTERFERON ALFA-2B | 1 | Unknown | U | 0 | ||||||||||
| 105293284 | 10529328 | 18 | I | INTRON A | INTERFERON ALFA-2B | 1 | Unknown | U | 0 | 48 | UG | ||||||||
| 105293284 | 10529328 | 19 | I | INTRON A | INTERFERON ALFA-2B | 1 | Unknown | U | 0 | 400 | MG | BID | |||||||
| 105293284 | 10529328 | 20 | I | INTRON A | INTERFERON ALFA-2B | 1 | Unknown | U | 0 | 200 | MG | BID | |||||||
| 105293284 | 10529328 | 21 | C | WARFARIN | WARFARIN | 1 | Unknown | 0 | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 105293284 | 10529328 | 1 | Liver transplant |
| 105293284 | 10529328 | 2 | Hepatitis C |
| 105293284 | 10529328 | 3 | Product used for unknown indication |
| 105293284 | 10529328 | 4 | Chronic hepatitis C |
| 105293284 | 10529328 | 7 | Chronic hepatitis C |
| 105293284 | 10529328 | 8 | Hepatitis cholestatic |
| 105293284 | 10529328 | 9 | Product used for unknown indication |
| 105293284 | 10529328 | 11 | Liver transplant |
| 105293284 | 10529328 | 14 | Chronic hepatitis C |
| 105293284 | 10529328 | 16 | Product used for unknown indication |
| 105293284 | 10529328 | 17 | Hepatitis C |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 105293284 | 10529328 | OT |
| 105293284 | 10529328 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 105293284 | 10529328 | Anaemia | |
| 105293284 | 10529328 | Ascites | |
| 105293284 | 10529328 | Drug ineffective | |
| 105293284 | 10529328 | Drug interaction | |
| 105293284 | 10529328 | Drug level increased | |
| 105293284 | 10529328 | Hepatic enzyme increased | |
| 105293284 | 10529328 | Hepatic function abnormal | |
| 105293284 | 10529328 | Hepatitis C | |
| 105293284 | 10529328 | Hepatitis cholestatic | |
| 105293284 | 10529328 | Jaundice | |
| 105293284 | 10529328 | Liver transplant | |
| 105293284 | 10529328 | Neutropenia | |
| 105293284 | 10529328 | Renal impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |